Genmab A (GMAB) Common Equity (2019 - 2026)

Genmab A has reported Common Equity for 5 years, with the latest figure at $5.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 2.82% year-over-year to $5.7 billion; the trailing twelve-month figure through Mar 2026 stood at $5.7 billion (down 2.82% YoY), and the FY2025 full-year result was $5.8 billion, up 13.82% from the prior year.
• Common Equity for Q1 2026 stood at $5.7 billion, down from $5.8 billion in the prior quarter.
• The five-year high for Common Equity was $5.8 billion in Q1 2025, with the low at $4.8 billion in Q3 2024.
• Historically, Common Equity has averaged $5.4 billion across 3 years, with a median of $5.5 billion in 2025.
• Annual changes were most pronounced in 2025 — Common Equity increased 19.99% — and 2026, when it decreased 2.82%.
• Genmab A's Common Equity stood at $5.1 billion in 2024, then advanced by 13.82% to $5.8 billion in 2025, then retreated by 2.82% to $5.7 billion in 2026.
• The last three Common Equity figures came in at $5.7 billion (Q1 2026), $5.8 billion (Q4 2025), and $5.8 billion (Q3 2025), per Business Quant data.